Provide scientific and strategic oversight for development candidates across therapeutic areas through close collaboration with PDMB program representatives, subject-matter experts and management as well as key partners in other functional areas, including but not limited to Nonclinical Safety, Translational Medicine, Quantitative Pharmacology, Regulatory Affairs, Formulation and others to ensure alignment on regulatory strategy and input for mechanistic investigations. Actively contribute to discussions regarding Clinical Pharmacology strategy, including starting dose, dose escalation, timing, design and interpretation of Ph1 studies, such as drug interactions, especial populations and human ADME amongst other studies, leveraging nonclinical data generated by PDMB.